Alnylam Pharmaceuticals, Inc. ALNY
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $3.7B | +65% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Operating income | $501.6M | +384% | FY ending Dec 31, 2025 |
| Net income | $313.7M | +213% | FY ending Dec 31, 2025 |
| Earnings per share | $2.33 | +207% | FY ending Dec 31, 2025 |
| Research & development | $1.3B | +17% | FY ending Dec 31, 2025 |
| Cash from operations | $524.1M | +6405% | FY ending Dec 31, 2025 |
| Capital spending | $58.7M | +71% | FY ending Dec 31, 2025 |
| Cash | $1.7B | +71% | FY ending Dec 31, 2025 |
| Shareholders' equity | $789.2M | +1076% | FY ending Dec 31, 2025 |
| Shares outstanding | 132M | +2% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 34 sales ($44.0M) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bryan SupranEVP, CLO and Secretary | Sold | 1,758 | $226.88 | $399K | Oct 2, 2026 |
| David E I PyottDirector | Soldpre-set plan5 fills | 3,830 | $299.18 avg | $1.1M | Jun 1, 2026 |
| Melissa MclaughlinChief Human Resources Officer | Soldpre-set plan5 fills | 2,286 | $330.42 avg | $755K | Apr 6, 2026 |
| Melissa MclaughlinChief Human Resources Officer | Soldpre-set plan9 fills | 1,624 | $319.59 avg | $519K | Apr 2, 2026 |
| Pushkal GargEVP Chief R&D | Soldpre-set plan4 fills | 2,404 | $323.96 avg | $779K | Mar 5, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Soldpre-set plan4 fills | 658 | $323.98 avg | $213K | Mar 5, 2026 |
| Yvonne GreenstreetChief Executive Officer, Director | Sold8 fills | 2,933 | $323.08 avg | $948K | Mar 4, 2026 |
| Jeffrey V. PoultonEVP, Chief Financial Officer | Sold8 fills | 2,468 | $323.08 avg | $797K | Mar 4, 2026 |
| Pushkal GargEVP Chief R&D | Soldpre-set plan8 fills | 2,309 | $323.08 avg | $746K | Mar 4, 2026 |
| Tolga TangulerEVP, Chief Commercial Officer | Sold8 fills | 2,309 | $323.08 avg | $746K | Mar 4, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Soldpre-set plan8 fills | 633 | $323.08 avg | $205K | Mar 4, 2026 |
| Pushkal GargEVP Chief R&D | Soldpre-set plan4 fills | 1,775 | $319.74 avg | $568K | Mar 3, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Soldpre-set plan4 fills | 1,652 | $319.73 avg | $528K | Mar 3, 2026 |
| Yvonne GreenstreetChief Executive Officer, Director | Sold10 fills | 6,799 | $327.65 avg | $2.2M | Mar 2, 2026 |
| Jeffrey V. PoultonEVP, Chief Financial Officer | Sold10 fills | 2,206 | $327.65 avg | $723K | Mar 2, 2026 |
| Pushkal GargEVP Chief R&D | Soldpre-set plan10 fills | 1,717 | $327.66 avg | $563K | Mar 2, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Soldpre-set plan10 fills | 1,598 | $327.65 avg | $524K | Mar 2, 2026 |
| Tolga TangulerEVP, Chief Commercial Officer | Sold10 fills | 1,598 | $327.65 avg | $524K | Mar 2, 2026 |
| Pushkal GargEVP Chief R&D | Soldpre-set plan5 fills | 4,627 | $331.34 avg | $1.5M | Feb 27, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Soldpre-set plan | 2,041 | $331.96 | $678K | Feb 17, 2026 |
| Yvonne GreenstreetChief Executive Officer, Director | Sold | 6,958 | $310.08 | $2.2M | Feb 13, 2026 |
| Pushkal GargEVP Chief R&D | Sold | 2,242 | $310.08 | $695K | Feb 13, 2026 |
| Jeffrey V. PoultonEVP, Chief Financial Officer | Sold | 2,242 | $310.08 | $695K | Feb 13, 2026 |
| Tolga TangulerEVP, Chief Commercial Officer | Sold | 1,959 | $310.08 | $607K | Feb 13, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Soldpre-set plan | 1,959 | $310.08 | $607K | Feb 13, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Soldpre-set plan6 fills | 2,290 | $370.33 avg | $848K | Jan 13, 2026 |
| Yvonne GreenstreetChief Executive Officer, Director | Sold21 fills | 9,577 | $362.86 avg | $3.5M | Jan 12, 2026 |
| Jeffrey V. PoultonEVP, Chief Financial Officer | Sold21 fills | 2,780 | $362.87 avg | $1.0M | Jan 12, 2026 |
| Pushkal GargEVP Chief R&D | Sold21 fills | 1,510 | $362.87 avg | $548K | Jan 12, 2026 |
| Tolga TangulerEVP, Chief Commercial Officer | Sold21 fills | 1,510 | $362.87 avg | $548K | Jan 12, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Soldpre-set plan21 fills | 1,510 | $362.87 avg | $548K | Jan 12, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Soldpre-set plan11 fills | 12,128 | $452.18 avg | $5.5M | Nov 17, 2025 |
| Yvonne GreenstreetChief Executive Officer, Director | Soldpre-set plan9 fills | 10,000 | $451.27 avg | $4.5M | Nov 13, 2025 |
| Yvonne GreenstreetChief Executive Officer, Director | Soldpre-set plan11 fills | 15,650 | $453.69 avg | $7.1M | Nov 12, 2025 |
Other insider moves (38): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Yvonne GreenstreetChief Executive Officer, Director | Award | 107 | – | – | Sep 19, 2026 |
| David E I PyottDirector | Option exercisepre-set plan | 3,830 | – | – | Jun 1, 2026 |
| Charles Elliott SigalDirector | Award | 671 | – | – | May 20, 2026 |
| Amy W SchulmanDirector | Award | 838 | – | – | May 20, 2026 |
| Colleen F ReitanDirector | Award | 671 | – | – | May 20, 2026 |
| David E I PyottDirector | Award | 671 | – | – | May 20, 2026 |
| Peter N KelloggDirector | Award | 671 | – | – | May 20, 2026 |
| Margaret A HamburgDirector | Award | 671 | – | – | May 20, 2026 |
| Olivier BrandicourtDirector | Award | 671 | – | – | May 20, 2026 |
| Dennis A AusielloDirector | Award | 671 | – | – | May 20, 2026 |
| Stuart A ArbuckleDirector | Award | 671 | – | – | May 20, 2026 |
| Amy W SchulmanDirector | Option exercise | 11,250 | $70.20 | $790K | May 13, 2026 |
| Jeffrey V. PoultonEVP, Chief Financial Officer | Award | 4,769 | – | – | Mar 2, 2026 |
| Pushkal GargEVP Chief R&D | Awardpre-set plan | 4,769 | – | – | Mar 2, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Awardpre-set plan | 3,688 | – | – | Mar 2, 2026 |
| Tolga TangulerEVP, Chief Commercial Officer | Award | 4,769 | – | – | Mar 2, 2026 |
| Bryan SupranEVP, CLO and Secretary | Award | 1,539 | – | – | Mar 2, 2026 |
| Yvonne GreenstreetChief Executive Officer, Director | Award | 13,844 | – | – | Mar 2, 2026 |
| Yvonne GreenstreetChief Executive Officer, Director | Option exercise | 5,921 | – | – | Feb 27, 2026 |
| Jeffrey V. PoultonEVP, Chief Financial Officer | Option exercise | 1,908 | – | – | Feb 27, 2026 |
| Tolga TangulerEVP, Chief Commercial Officer | Option exercise | 1,666 | – | – | Feb 27, 2026 |
| Pushkal GargEVP Chief R&D | Option exercisepre-set plan | 1,908 | – | – | Feb 27, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Award | 158 | – | – | Feb 23, 2026 |
| Pushkal GargEVP Chief R&D | Award | 4,579 | – | – | Feb 12, 2026 |
| Yvonne GreenstreetChief Executive Officer, Director | Award | 14,209 | – | – | Feb 12, 2026 |
| Tolga TangulerEVP, Chief Commercial Officer | Award | 4,000 | – | – | Feb 12, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Awardpre-set plan | 4,000 | – | – | Feb 12, 2026 |
| Jeffrey V. PoultonEVP, Chief Financial Officer | Award | 4,579 | – | – | Feb 12, 2026 |
| Pushkal GargEVP Chief R&D | Award | 3,800 | – | – | Jan 11, 2026 |
| Yvonne GreenstreetChief Executive Officer, Director | Award | 19,003 | – | – | Jan 11, 2026 |
| Jeffrey V. PoultonEVP, Chief Financial Officer | Award | 6,193 | – | – | Jan 11, 2026 |
| Tolga TangulerEVP, Chief Commercial Officer | Award | 3,800 | – | – | Jan 11, 2026 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Awardpre-set plan | 3,800 | – | – | Jan 11, 2026 |
| Yvonne GreenstreetChief Executive Officer, Director | Option exercise4 fills | 4,697 | $106.40 avg | $500K | Nov 26, 2025 |
| Yvonne GreenstreetChief Executive Officer, Director | Tax withholding | 1,121 | $445.12 | $499K | Nov 26, 2025 |
| Kevin Joseph FitzgeraldCSO & EVP, Head of Research | Option exercisepre-set plan | 8,161 | $119.13 | $972K | Nov 17, 2025 |
| Yvonne GreenstreetChief Executive Officer, Director | Option exercisepre-set plan | 10,000 | $119.13 | $1.2M | Nov 13, 2025 |
| Yvonne GreenstreetChief Executive Officer, Director | Option exercisepre-set plan2 fills | 15,650 | $115.94 avg | $1.8M | Nov 12, 2025 |
Trades by members of Congress
1 member reported 0 buys and 1 sale since May 12, 2025. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Jefferson Shreve R | Sold | $15K–$50K | May 12, 2025 | Jun 22, 2025 | Self |
Latest SEC filings
- Insider plans to sell 144 · Oct 2, 2026
- Quarterly report 10-Q · Jul 30, 2026
- News filing: Quarterly results 8-K · Jul 30, 2026
- Insider plans to sell 144 · Jun 1, 2026
- News filing: Executive or board change, Shareholder vote results 8-K · May 27, 2026
- Quarterly report 10-Q · Apr 30, 2026
- News filing: Quarterly results 8-K · Apr 30, 2026
- Shareholder meeting proxy DEF 14A · Apr 6, 2026
- Insider plans to sell 144 · Apr 6, 2026
- Insider plans to sell 144 · Mar 5, 2026
- Insider plans to sell 144 · Mar 5, 2026
- News filing: Executive or board change 8-K · Mar 4, 2026
- Insider plans to sell 144 · Mar 3, 2026
- Insider plans to sell 144 · Mar 3, 2026
- Insider plans to sell 144 · Feb 27, 2026
- Insider plans to sell 144 · Feb 17, 2026
- Annual report 10-K · Feb 12, 2026
- News filing: Quarterly results 8-K · Feb 12, 2026
- Insider plans to sell 144 · Jan 13, 2026
- News filing: Quarterly results 8-K · Jan 12, 2026
- News filing: Other news 8-K · Dec 11, 2025
- News filing: Executive or board change 8-K · Dec 3, 2025
- Insider plans to sell 144 · Nov 17, 2025
- Insider plans to sell 144 · Nov 12, 2025
- Quarterly report 10-Q · Oct 30, 2025
About Alnylam Pharmaceuticals, Inc.
Business description
- Industry
- Pharmaceutical Preparations
- Sector
- Life Sciences
- Headquarters
- Cambridge, MA
- Fiscal year ends
- December 31
- Exchange
- Nasdaq
- Filer size
- Large accelerated filer
- Formerly
- ALNYLAM PHARMACEUTICALS INC
- SEC company number (CIK)
- 1178670
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.